Vairavan Latha 4
4 · Arcutis Biotherapeutics, Inc. · Filed Mar 3, 2026
Insider Transaction Report
Form 4
Vairavan Latha
SVP Chief Financial Officer
Transactions
- Award
Common Stock
[F1]2026-02-27+27,000→ 90,607 total - Sale
Common Stock
[F2][F3]2026-03-02$25.16/sh−2,772$69,745→ 87,835 total - Sale
Common Stock
[F2][F4]2026-03-02$25.91/sh−81$2,099→ 87,754 total - Award
Stock Option (right to buy)
[F5]2026-02-27+70,000→ 70,000 totalExercise: $26.97Exp: 2036-02-27→ Common Stock (70,000 underlying)
Footnotes (5)
- [F1]Constitute Restricted Stock Units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting, in which 25% of the RSUs vest annually on March 1, (the "Vesting Commencement Date"), of each year beginning March 1, 2027, subject to the Reporting Person's continued service to the Issuer.
- [F2]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs.
- [F3]The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.69 to $25.67, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.70 to $26.10, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F5]1/48th of the shares subject to the option vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.
Signature
/s/ Masaru Matsuda, as Attorney-in-Fact for Latha Vairavan|2026-03-03